Tecan IBL International offers a comprehensive range of ELISAs, antibodies, immunoassays and recombinant proteins for research use only.
Research into the antigenicity of cytokines, such as interferons, has revealed that although these molecules are typically not immunogenic in homologous systems—because antibodies are usually not produced against "self" antigens—naturally occurring or therapeutically induced antibodies against cytokines, including interferons, tumor necrosis factors (TNF), interleukins (IL), and various growth factors, can occur. These antibodies generally inhibit the function of cytokines, potentially leading to varying degrees of cytokine deficiency.
The development of antibodies against autoantigens or therapeutic drugs is generally considered undesirable. Such antibodies can play a significant role in the pathology of autoimmune diseases and can interfere with the pharmacological effects of drugs, including exogenously administered cytokines.
Natural Antibodies:
- IFN-alpha: Antibodies against IFN-alpha have been reported in patients with various autoimmune disorders, including systemic lupus erythematosus (SLE). These antibodies have also been detected in patients with herpes zoster and varicella zoster infections. Additionally, spontaneous antibodies to IFN-alpha have been observed in patients with various cancers.
Therapeutically Induced Antibodies:
- IFN-alpha: The formation of antibodies against IFN-alpha has been documented in patients following treatment with different human IFN preparations, irrespective of their composition or subtype. It has been observed that relapses after successful IFN-alpha therapy often coincide with the development of neutralizing antibodies against the cytokine.
Leukemias/Lymphomas:
- Clinical resistance and the presence of IFN-alpha antibodies have been identified in patients with conditions such as hairy cell leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, essential thrombocythemia, preleukemia, and Kaposi's sarcoma.
Solid Tumors:
- Treatment of patients with solid tumors can also induce the formation of IFN-alpha antibodies. This has been documented in patients with malignant melanoma, renal cell carcinoma, nasopharyngeal carcinoma, breast carcinoma, various advanced carcinomas, urinary bladder carcinoma, and genital as well as respiratory papillomatosis.
This ELISA Kit from Tecan IBL International is for research use only.
Tecan IBL International offers a comprehensive range of ELISAs, immunoassays, antibodies and recombinant proteins.
Explore the full range >